A single nucleotide variant of human PARP1 determines response to PARP inhibitors

Area of Science:

• Oncology
• Genomics
• Pharmacology

Background:

• Novel cancer therapies, including poly-ADP ribose polymerase inhibitors (PARPis), offer promise but require patient-specific treatment matching.
• PARPis are effective in certain cancers, particularly those associated with BRCA mutations, via synthetic lethality, but response prediction remains a challenge.

Purpose of the Study:

• To identify a genomic marker that predicts patient response to PARP inhibitors (PARPis).
• To investigate the correlation between a specific human PARP1 single-nucleotide polymorphism (SNP) and in vitro response to PARPis across all indications.

Main Methods:

• Identification and analysis of a specific single-nucleotide polymorphism (SNP) in the human PARP1 gene.
• In vitro correlation studies to assess the relationship between the PARP1-SNP and response to PARPis.

Main Results:

• A specific PARP1 single-nucleotide polymorphism (SNP) was identified as a genomic marker correlating with PARPi response.
• The identified SNP influences mRNA reshaping and levels, altering protein structure and binding sites.
• The PARP1-SNP status is critical for predicting patient response to PARPis.

Conclusions:

• The identified PARP1-SNP is a potential predictive biomarker for PARPi therapy.
• Understanding the impact of this SNP on PARP1 function is crucial for personalized cancer treatment strategies.
• This discovery could lead to improved patient selection for PARPi treatment, enhancing therapeutic outcomes.